VYSCOXA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VYSCOXA (VYSCOXA).
Viscosupplementation agent; hyaluronic acid derivative that replaces synovial fluid, providing lubrication and shock absorption in osteoarthritic joints.
| Metabolism | Not metabolized; cleared by lymphatic system and degraded locally. |
| Excretion | Primarily renal excretion of unchanged drug (60-70%) via glomerular filtration and active tubular secretion; approximately 20% biliary/fecal elimination. |
| Half-life | Terminal elimination half-life of 7-9 hours in patients with normal renal function; prolonged to 20-30 hours in moderate renal impairment (CrCl 30-50 mL/min). |
| Protein binding | 95-98% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.15-0.25 L/kg, indicating limited extravascular distribution; higher Vd in obese patients (up to 0.35 L/kg). |
| Bioavailability | Oral: 70-85% with moderate variability due to first-pass metabolism; intramuscular: approximately 90%. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: within 5 minutes; Intramuscular: 15-30 minutes. |
| Duration of Action | 10-12 hours after oral administration; up to 24 hours after intravenous dosing due to sustained plasma levels. |
Intraocular injection: 0.25 mg (0.1 mL of 2.5 mg/mL solution) administered at baseline, month 1, and month 2, then every 3 months.
| Dosage form | SUSPENSION |
| Renal impairment | No dose adjustment required for renal impairment; safety and efficacy not established in severe renal impairment (eGFR <30 mL/min/1.73 m²). |
| Liver impairment | No dose adjustment required for hepatic impairment; not studied in Child-Pugh C cirrhosis. |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established. |
| Geriatric use | No specific dose adjustment; limited data in patients ≥75 years, consider increased risk of adverse events. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VYSCOXA (VYSCOXA).
| Breastfeeding | Limited human data; vortioxetine is excreted in breast milk. M/P ratio unknown due to lack of quantitative studies. Use caution; consider risk of infant exposure (drowsiness, reduced feeding). |
| Teratogenic Risk | Vyscoxa (vortioxetine) is classified as Pregnancy Category C. First trimester: Limited data; animal studies show adverse effects at high doses but no structural malformations in humans. Second trimester: Risk of serotonin syndrome in neonate if used near term. Third trimester: Potential for persistent pulmonary hypertension of the newborn (PPHN) and neonatal adaptation syndrome (irritability, feeding difficulties). |
■ FDA Black Box Warning
None.
| Serious Effects |
Known hypersensitivity to hyaluronic acid or any component of the product; joint infection or skin disease at injection site.
| Precautions | Do not use in patients with known hypersensitivity to hyaluronic acid preparations; avoid injection in infected or inflamed joints; do not use concurrently with disinfectants containing quaternary ammonium salts; may cause transient local reactions (pain, swelling, effusion). |
Loading safety data…
| Fetal Monitoring | Monitor for maternal serotonin syndrome (agitation, hyperthermia, clonus) and fetal growth via ultrasound. Assess neonatal adaptation (respiratory distress, feeding problems) at delivery. For lactation, observe infant for sedation, poor feeding, and irritability. |
| Fertility Effects | Animal studies show reduced fertility at high doses. Human data: Possible reversible decrease in libido and ejaculatory dysfunction; no conclusive effect on conception rates. |